ESC 365 - Angiogenic gene therapy for refractory angina: results of the epicardial delivery of XC001 gene therapy for refractory angina coronary treatment (EXACT) phase 2 trial

ESC Professional Premium Access

Angiogenic gene therapy for refractory angina: results of the epicardial delivery of XC001 gene therapy for refractory angina coronary treatment (EXACT) phase 2 trial

Session: Risk stratification and treatment options in chronic coronary syndrome

Topic: Pharmacotherapy

Speaker: Professor T. Povsic (Durham, US)

Event: ESC Congress 2023

Congress Presentation

Add to my library

About the speaker

Professor Thomas Povsic

Duke Clinical Research Institute, Durham (United States of America)

0 follower

7 more presentations in this session

Treatment of microvascular angina with the coronary sinus reducer: a first experience

Speaker: Doctor E. Gnan (Milan, IT)

Diagnostic performance of machine learning on 12-lead electrocardiogram for predicting multi-vessel coronary vasospastic angina

Speaker: Doctor Y. Misu (Yokohama, JP)

Exercise ECG and myocardial perfusion SPECT show high prognostic value up to four years after examination

Speaker: Mr M. Kraen (Malmo, SE)

The efficacy of coronary sinus reduction in refractory angina: A meta-analysis

Speaker: Doctor P. Theofilis (Athens, GR)

Changes in myocardial perfusion after coronary sinus reducer implantation for refractory angina - assessment using fully automated quantitative stress perfusion cardiac MRI

Speaker: Doctor K. Cheng (London, GB)

Access the full session

Risk stratification and treatment options in chronic coronary syndrome

Speakers: Professor T. Povsic, Doctor E. Gnan, Doctor Y. Misu, Mr M. Kraen, Doctor P. Theofilis...

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources